These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8597088)

  • 21. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
    Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
    Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antisense therapeutics.
    Agrawal S; Zhao Q
    Curr Opin Chem Biol; 1998 Aug; 2(4):519-28. PubMed ID: 9736926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue.
    Iversen P
    Anticancer Drug Des; 1991 Dec; 6(6):531-8. PubMed ID: 1772568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
    Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys.
    Webb MS; Tortora N; Cremese M; Kozlowska H; Blaquiere M; Devine DV; Kornbrust DJ
    Antisense Nucleic Acid Drug Dev; 2001 Jun; 11(3):155-63. PubMed ID: 11446591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
    Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats.
    Zhang R; Lu Z; Zhao H; Zhang X; Diasio RB; Habus I; Jiang Z; Iyer RP; Yu D; Agrawal S
    Biochem Pharmacol; 1995 Aug; 50(4):545-56. PubMed ID: 7646561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase.
    Henry SP; Monteith D; Bennett F; Levin AA
    Anticancer Drug Des; 1997 Jul; 12(5):409-20. PubMed ID: 9236856
    [No Abstract]   [Full Text] [Related]  

  • 29. Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice.
    Rifai A; Brysch W; Fadden K; Clark J; Schlingensiepen KH
    Am J Pathol; 1996 Aug; 149(2):717-25. PubMed ID: 8702009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines.
    Agrawal S; Tan W; Cai Q; Xie X; Zhang R
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):245-9. PubMed ID: 9212919
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.
    Zhang R; Diasio RB; Lu Z; Liu T; Jiang Z; Galbraith WM; Agrawal S
    Biochem Pharmacol; 1995 Mar; 49(7):929-39. PubMed ID: 7741765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense phosphorothioate oligonucleotides: selective killing of the intracellular parasite Leishmania amazonensis.
    Ramazeilles C; Mishra RK; Moreau S; Pascolo E; Toulmé JJ
    Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7859-63. PubMed ID: 8058724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative three-dimensional analysis and diffusion modeling of oligonucleotide concentrations after direct intraparenchymal brain infusion.
    Haar PJ; Stewart JE; Gillies GT; Prabhu SS; Broaddus WC
    IEEE Trans Biomed Eng; 2001 May; 48(5):560-9. PubMed ID: 11341530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
    Saijo Y; Perlaky L; Wang H; Busch H
    Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides.
    Zhao Q; Matson S; Herrera CJ; Fisher E; Yu H; Krieg AM
    Antisense Res Dev; 1993; 3(1):53-66. PubMed ID: 8495106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats.
    Lendvai G; Velikyan I; Bergström M; Estrada S; Laryea D; Välilä M; Salomäki S; Långström B; Roivainen A
    Eur J Pharm Sci; 2005 Sep; 26(1):26-38. PubMed ID: 15941654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats.
    Zhang R; Lu Z; Zhang X; Zhao H; Diasio RB; Liu T; Jiang Z; Agrawal S
    Clin Chem; 1995 Jun; 41(6 Pt 1):836-43. PubMed ID: 7768001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of aspirin on protein binding and tissue disposition of oligonucleotide phosphorothioate in rats.
    Agrawal S; Zhang X; Cai Q; Kandimalla ER; Manning A; Jiang Z; Marcel T; Zhang R
    J Drug Target; 1998; 5(4):303-12. PubMed ID: 9713979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects.
    Zhang R; Yan J; Shahinian HK; Amin G; Lu Z; Liu T; Saag MS; Jiang Z; Temsamani J; Martin RR
    Clin Pharmacol Ther; 1995 Jul; 58(1):44-53. PubMed ID: 7628182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.
    Henry SP; Miner RC; Drew WL; Fitchett J; York-Defalco C; Rapp LM; Levin AA
    Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2646-51. PubMed ID: 11581212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.